{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:10:56Z","timestamp":1788865856696,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z221100007422064"],"award-info":[{"award-number":["Z221100007422064"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z221100007422056"],"award-info":[{"award-number":["Z221100007422056"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20250484980"],"award-info":[{"award-number":["20250484980"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijantimicag.2026.107889","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:12:16Z","timestamp":1781737936000},"page":"107889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heteroresistance of tuberculosis: Mechanism, detection, and clinical treatment"],"prefix":"10.1016","volume":"67","author":[{"given":"Guyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-9807","authenticated-orcid":false,"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107889_bib0001","series-title":"Global tuberculosis report 2025. World Health Organization","year":"2025"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","article-title":"Mechanisms and clinical relevance of bacterial heteroresistance","volume":"17","author":"Andersson","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00180-19","article-title":"The changing paradigm of Drug-Resistant Tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02181-24","article-title":"Investigation of bedaquiline heteroresistance among Mycobacterium tuberculosis isolates from Pakistan","volume":"13","author":"Rashid","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10.1016\/j.ijantimicag.2026.107889_bib0005","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/infdis\/jiab011","article-title":"Lesion Heterogeneity and Long-Term Heteroresistance in Multidrug-Resistant Tuberculosis","volume":"224","author":"Chen","year":"2021","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0006","doi-asserted-by":"crossref","first-page":"23834","DOI":"10.1038\/s41598-024-68605-2","article-title":"HIV co-infection increases the risk of post-tuberculosis mortality among persons who initiated treatment for drug-resistant tuberculosis","volume":"14","author":"Salindri","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0007","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin Res Ed.)"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12941-021-00478-z","article-title":"Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis","volume":"20","author":"Ye","year":"2021","journal-title":"Annals Clin Microbiol Antimic"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.938032","article-title":"Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement","volume":"12","author":"Singh","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0010","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/jac\/dkt082","article-title":"Co-occurrence of amikacin-resistant and -susceptible Mycobacterium tuberculosis isolates in clinical samples from Beijing, China","volume":"68","author":"Zhang","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0011","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/JCM.03507-14","article-title":"Mixed Infections and Rifampin Heteroresistance among Mycobacterium tuberculosis Clinical Isolates","volume":"53","author":"Zheng","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10.1016\/j.ijantimicag.2026.107889_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00720-21","article-title":"Detection of Pyrazinamide Heteroresistance in Mycobacterium Tuberculosis","volume":"65","author":"Werngren","year":"2021","journal-title":"Antimicro Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijantimicag.2026.107889_bib0013","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/infdis\/jis601","article-title":"Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients","volume":"206","author":"Sun","year":"2012","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.ijantimicag.2026.107889_bib0014","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/infdis\/jiu040","article-title":"Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests","volume":"209","author":"Zetola","year":"2014","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107889_bib0015","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1093\/infdis\/jiae042","article-title":"Uncovering the Bronchoalveolar Single-Cell landscape of patients with Pulmonary Tuberculosis with human Immunodeficiency Virus Type 1 coinfection","volume":"230","author":"Xiao","year":"2024","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0016","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/jac\/dkv447","article-title":"Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir\/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB","volume":"71","author":"Pandie","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12941-024-00694-3","article-title":"The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran","volume":"23","author":"Madadi-Goli","year":"2024","journal-title":"Annals Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0018","doi-asserted-by":"crossref","first-page":"102747","DOI":"10.1016\/j.ebiom.2020.102747","article-title":"Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment","volume":"55","author":"Nimmo","year":"2020","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107889_bib0019","doi-asserted-by":"crossref","first-page":"e00159","DOI":"10.1128\/CMR.00159-19","article-title":"Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters","volume":"33","author":"Sarathy","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107889_bib0020","doi-asserted-by":"crossref","first-page":"e02266","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme drug tolerance of Mycobacterium tuberculosis in Caseum","volume":"62","author":"Sarathy","year":"2018","journal-title":"Antimicrob Agent Chemother"},{"issue":"9","key":"10.1016\/j.ijantimicag.2026.107889_bib0021","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1164\/rccm.201711-2333OC","article-title":"Drug-penetration gradients associated with acquired drug resistance in patients with Tuberculosis","volume":"198","author":"Dheda","year":"2018","journal-title":"Amer J Resp Crit Care Med"},{"issue":"10","key":"10.1016\/j.ijantimicag.2026.107889_bib0022","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ijantimicag.2026.107889_bib0023","first-page":"907","article-title":"Morphological variability and cell-wall deficiency in Mycobacterium tuberculosis \u2018heteroresistant\u2019 strains","volume":"9","author":"Michailova","year":"2005","journal-title":"The international journal of tuberculosis and lung disease\u202f: the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0024","doi-asserted-by":"crossref","first-page":"2534656","DOI":"10.1080\/22221751.2025.2534656","article-title":"Mixed infections and heteroresistance of Mycobacterium tuberculosis among multidrug-resistant tuberculosis in China: a genomic epidemiology study","volume":"14","author":"Liu","year":"2025","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.612675","article-title":"Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment","volume":"12","author":"Allu\u00e9-Guardia","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdiacomp.2014.09.007","article-title":"Type 2 diabetes mellitus and its influence in the development of multidrug resistance tuberculosis in patients from southeastern Mexico","volume":"29","author":"P\u00e9rez-Navarro","year":"2015","journal-title":"J Diabetes Complications"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0027","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/biology12040525","article-title":"Heteroresistance of Mycobacterium tuberculosis in the Sputum Detected by Droplet Digital PCR","volume":"12","author":"Aung","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijregi.2021.12.007","article-title":"Genotypic and phenotypic drug-resistance detection and prevalence of heteroresistance in patients with isoniazid- and multidrug-resistant tuberculosis in Ethiopia","volume":"2","author":"Getahun","year":"2022","journal-title":"IJID Reg"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107889_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01084-24","article-title":"Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis","volume":"69","author":"Vogensen","year":"2025","journal-title":"Antimicrob Agent Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011000","article-title":"High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance","volume":"19","author":"Martinecz","year":"2023","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0031","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1128\/JCM.02532-16","article-title":"Non-pncA gene-mutated but pyrazinamide-resistant Mycobacterium tuberculosis: why is that?","volume":"55","author":"Werngren","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0032","doi-asserted-by":"crossref","unstructured":"World Health Organization (2024). Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. World Health Organization. https:\/\/doi.org\/10.2471\/B09123. License: CC BY-NC-SA 3.0 IGO","DOI":"10.2471\/B09123"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0033","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1038\/s41598-019-48289-9","article-title":"Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations","volume":"9","author":"Rigouts","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0034","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12890-020-1172-4","article-title":"Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients","volume":"20","author":"Kabir","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107889_bib0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/ijmy.ijmy_116_23","article-title":"Fluoroquinolone resistance mutations among Mycobacterium tuberculosis and their interconnection with treatment outcome","volume":"12","author":"Dixit","year":"2023","journal-title":"Int J Mycobact"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0036","doi-asserted-by":"crossref","unstructured":"Conradie, F., Diacon, A.H., Ngubane, N., Howell, P., Everitt, D., Crook, A.M., et al (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New Eng J Med 382(10), 893\u2013902.","DOI":"10.1056\/NEJMoa1901814"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0037","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","article-title":"Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107889_bib0038","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jinf.2021.02.004","article-title":"Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey","volume":"82","author":"Wang","year":"2021","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01275-23","article-title":"Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC","volume":"68","author":"Villellas","year":"2024","journal-title":"Antimicrob Agent Chemother"},{"issue":"8","key":"10.1016\/j.ijantimicag.2026.107889_bib0040","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J Antimicrob Chem"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0041","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijtb.2025.09.005","article-title":"Delamanid or pretomanid for treatment of multidrug resistant tuberculosis\u2014spoilt for choice?","volume":"73","author":"Sharma","year":"2026","journal-title":"Indian J Tuberc"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0042","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/thorax-2024-221409","article-title":"Heteroresistance in tuberculosis: are we missing drug-resistant bacteria hiding in plain sight?","volume":"79","author":"Park","year":"2024","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0043","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1465-9921-7-99","article-title":"Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia","volume":"7","author":"Shamputa","year":"2006","journal-title":"Resp Res"},{"issue":"5","key":"10.1016\/j.ijantimicag.2026.107889_bib0044","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jac\/dkz564","article-title":"Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact","volume":"75","author":"Van Rie","year":"2020","journal-title":"J Antimicrob Chem"},{"issue":"8","key":"10.1016\/j.ijantimicag.2026.107889_bib0045","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JCM.00553-13","article-title":"Rifampin drug resistance tests for tuberculosis: challenging the gold standard","volume":"51","author":"Van Deun","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0046","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1128\/JCM.02489-13","article-title":"Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB\/RIF are associated with poor clinical outcomes","volume":"52","author":"Zetola","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0047","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.diagmicrobio.2019.02.008","article-title":"Detection of Mycobacterium tuberculosis in paucibacillary sputum: performances of the Xpert MTB\/RIF ultra compared to the Xpert MTB\/RIF, and IS6110 PCR","volume":"94","author":"Kolia-Diafouka","year":"2019","journal-title":"Diagn Microb Infect Dis"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0048","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1128\/JCM.00143-12","article-title":"Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature coding","volume":"50","author":"Chakravorty","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.ijantimicag.2026.107889_bib0049","doi-asserted-by":"crossref","first-page":"e00717","DOI":"10.1128\/JCM.00717-19","article-title":"How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?","volume":"57","author":"Ng","year":"2019","journal-title":"J Clin Microb"},{"issue":"6","key":"10.1016\/j.ijantimicag.2026.107889_bib0050","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01884-22","article-title":"Quantification of Isoniazid-Heteroresistant Mycobacterium tuberculosis Using Droplet Digital PCR","volume":"61","author":"Zhang","year":"2023","journal-title":"J Clin Microb"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0051","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/JCM.02639-13","article-title":"Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB","volume":"52","author":"Luetkemeyer","year":"2014","journal-title":"J Clin Microb"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107889_bib0052","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1128\/JCM.02271-10","article-title":"Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay","volume":"49","author":"Chakravorty","year":"2011","journal-title":"J Clin Microb"},{"issue":"6","key":"10.1016\/j.ijantimicag.2026.107889_bib0053","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jmoldx.2023.02.003","article-title":"Comparison of the diagnostic performance of MeltPro and next-generation sequencing in determining Fluoroquinolone Resistance in multidrug-resistant Tuberculosis isolates","volume":"25","author":"Hu","year":"2023","journal-title":"J Mol Diag\u202f: JMD"},{"issue":"6336","key":"10.1016\/j.ijantimicag.2026.107889_bib0054","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1126\/science.aam9321","article-title":"Nucleic acid detection with CRISPR-Cas13a\/C2c2","volume":"356","author":"Gootenberg","year":"2017","journal-title":"Science (New York, N.Y.)"},{"issue":"11","key":"10.1016\/j.ijantimicag.2026.107889_bib0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s13059-014-0490-3","article-title":"Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient","volume":"15","author":"Eldholm","year":"2014","journal-title":"Gen Biol"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0056","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12864-015-2067-2","article-title":"Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates","volume":"16","author":"Black","year":"2015","journal-title":"BMC Genom"},{"issue":"9","key":"10.1016\/j.ijantimicag.2026.107889_bib0057","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1128\/JCM.00744-11","article-title":"Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based single nucleotide polymorphism genotyping assay using iPLEX gold technology for identification of Mycobacterium tuberculosis complex species and lineages","volume":"49","author":"Bouakaze","year":"2011","journal-title":"J Clin Microb"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0058","doi-asserted-by":"crossref","first-page":"ofae320","DOI":"10.1093\/ofid\/ofae320","article-title":"Culture-free whole Genome sequencing of Mycobacterium Tuberculosis using ligand-mediated bead enrichment method","volume":"11","author":"Vasanthaiah","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0059","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01907-21","article-title":"Comparative performance of Genomic methods for the detection of Pyrazinamide resistance and Heteroresistance in Mycobacterium Tuberculosis","volume":"60","author":"Whitfield","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0060","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/thorax-2023-220202","article-title":"Challenging the gold standard: the limitations of molecular assays for detection of Mycobacterium tuberculosis heteroresistance","volume":"79","author":"Danchuk","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0061","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4314\/ahs.v22i1.65","article-title":"Mycobacterium tuberculosis mixed infections and drug resistance in sub-Saharan Africa: a systematic review","volume":"22","author":"Micheni","year":"2022","journal-title":"Afr Health Sci"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107889_bib0062","doi-asserted-by":"crossref","first-page":"107666","DOI":"10.1016\/j.ijantimicag.2025.107666","article-title":"Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms","volume":"67","author":"Hong","year":"2026","journal-title":"Int J Antimicrob Agent"},{"issue":"8","key":"10.1016\/j.ijantimicag.2026.107889_bib0063","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00356-25","article-title":"Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing","volume":"69","author":"Ismail","year":"2025","journal-title":"Antimicrob Agent Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0064","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01573-20","article-title":"Disputed rpoB mutations in Mycobacterium Tuberculosis and Tuberculosis treatment outcomes","volume":"65","author":"Lin","year":"2021","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11538-008-9361-y","article-title":"Latent coinfection and the maintenance of strain diversity","volume":"71","author":"Colijn","year":"2009","journal-title":"Bull Math Biol"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0066","doi-asserted-by":"crossref","first-page":"102120","DOI":"10.1016\/j.tube.2021.102120","article-title":"Deep whole-genome sequencing reveals no evidence for heteroresistance influencing treatment outcomes among drug-susceptible tuberculosis patients","volume":"130","author":"Chen","year":"2021","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107889_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-087218","article-title":"Impact of HIV coinfection on tuberculosis treatment outcomes in Ethiopia: a systematic review and meta-analysis","volume":"14","author":"Mekonen","year":"2024","journal-title":"BMJ open"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0068","doi-asserted-by":"crossref","first-page":"16302","DOI":"10.1073\/pnas.0808746105","article-title":"Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines","volume":"105","author":"Cohen","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2026.107889_bib0069","doi-asserted-by":"crossref","unstructured":"Shin, S.S., Modongo, C., Baik, Y., Allender, C., Lemmer, D., Colman, R.E., et al (2018). Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. J Infect Dis 218(12), 1974\u20131982.","DOI":"10.1093\/infdis\/jiy480"},{"issue":"4","key":"10.1016\/j.ijantimicag.2026.107889_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom","year":"2019","journal-title":"PLoS Med"},{"issue":"17","key":"10.1016\/j.ijantimicag.2026.107889_bib0071","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1073\/pnas.1704376114","article-title":"Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis","volume":"114","author":"Vilch\u00e8ze","year":"2017","journal-title":"Proc Nat Acad Sci United States Amer"},{"issue":"9","key":"10.1016\/j.ijantimicag.2026.107889_bib0072","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00592-22","article-title":"Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species","volume":"66","author":"Shee","year":"2022","journal-title":"Antimicrob Agent Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:48:10Z","timestamp":1788864490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926001767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0924857926001767"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107889","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heteroresistance of tuberculosis: Mechanism, detection, and clinical treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107889"}}